Dual peroxisome proliferator-activated receptor agonist demonstrates significant lipid benefits

Twice-daily danuglipron was being studied in a phase 2 study in adults with obesity. Pfizer is now conducting a pharmacokinetic study for a once-daily formulation.

A new survey finds that more people are using semaglutide and other GLP-1 therapies to lose less than 15 pounds.

Patients taking Mounjaro after a lifestyle intervention saw a weight reduction of almost 20%.

Svetlana Mojsov, Ph.D., was a key part of the team that discovered the function of the hormone glucagon-like peptide 1 (GLP-1) and its role in diabetes and weight loss.

Almost half of adults surveyed by KFF would be interested in taking a weight-loss drug, including many who say they only want to lose a little weight.

Researchers say capping insulin costs at $35 a month has the potential to lower events and costs related to diabetes, such as amputations, vision loss, and heart attacks.